Table 2. Sensitivity of the Cytosponge-TFF3 in different groups of patients (full dataset in S2 and S3 Tables).
| Patients | Total Number | TFF3 Positive | TFF3 Negative | Sensitivity (95% CI) |
|---|---|---|---|---|
| All BE patients (≥C1 or ≥M3) | 596 | 476 | 120 | 79.9% (76.4%–83.0%) |
| Segment length | ||||
| ≥C1 | 533 | 434 | 109 | 79.5% (75.9%–82.9%) |
| ≥C2 | 416 | 349 | 67 | 83.9% (80.0%–87.3%) |
| ≥C3 | 320 | 279 | 41 | 87.2% (83.0%–90.6%) |
| Dysplasia | ||||
| NDBE | 372 | 294 | 78 | 79.0% (74.5%–83.0%) |
| Indefinite for dysplasia | 46 | 34 | 12 | 73.9% (58.9%–85.7%) |
| LGD | 77 | 63 | 14 | 80.5% (69.9%–88.7%) |
| HGD/IMC | 101 | 85 | 16 | 84.2% (75.6%–90.7%) |
| Patients having two Cytosponge tests | 107 | 95 | 11 | 89.7% (82.3%–94.8%) |
C, Circumferential length; IMC, intramucosal carcinoma; LGD, low grade dysplasia; M, maximal length; NDBE, non-dysplastic BE.